RB-E2F signaling pathway is often inactivated in cancer due to various reasons including RB1 loss, RB hyperphosphorylation through increased activity of CDK4/CDK6, or E2F hyperphosphorylation, all of which prevent repression of E2Fs from binding to downstream targets. This evidence concerns the gene CDK6 and cancer.